

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **MARAPHARM VENTURES INC. (Marapharm or the "Company")** (the "Issuer").

Trading Symbol: **MDM**

Number of Outstanding Listed Securities: **136,187,202**

Date: **July 6, 2018**

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

- **Green Leaf Dispensary** *The Company purchased an operational dispensary, Green Leaf Wellness, located in Desert Hot Springs California. Management reports a daily average surge in sales of 300% since the acquisition on February 13, 2018.*
- **California cultivation facilities** *The Company is proceeding with the development and licensing on two properties for cultivation and processing in Desert Hot Springs, California.*
- **Nevada cultivation facilities** *On June 4th, a member from the State of Nevada, Department of Taxation met with Kurt Keating, Director of Operations, to perform a "walk-through" of both buildings. Final approval from the state will be granted, contingent on the city providing the Certificates of Occupancy.*

Six City of North Las Vegas Recreational and Medical Cannabis Cultivation and Production Business Licenses have been renewed and reissued for 2018-2019.

Three State of Nevada Medical Certificates for Production and Cultivation have been renewed and reissued for 2018-2019. Three Recreational Certificates are currently being processed for annual renewal and reissuance.

Three Secretary of State, Nevada State Annual Business Licences for Marapharm Las Vegas LLC, Econeveda LLC and Phenofarm NV LLC have all received state acceptance and renewal for 2018 -2019.

Propagation of several thousand clones began in June from the mother plants of the top five strains chosen for the Nevada market by the Company's Lead Cultivators.

The next phase of construction is the 65,000 sq. ft. three storey cultivation and production facility, the building has been ordered and collaboration between the American Buildings Company and Corporate Architects and Engineers has begun.

- **Washington cultivation facilities** *In Washington renovations are proceeding as scheduled.*
- **Washington Sun-Grown** *The Company closed the foregoing transactions and acquired certain operational assets, land and water rights related to two licensed cannabis producers and processors operating in Tonasket, Washington.*
- **Canadian application** *Amendments will be made to our Health Canada application to comply with the new regulations (ACMPR), as well as adjusting its current application to include the processing of medical marijuana.*
- **Financing** *The Company announced a non-brokered private placement unit offering announced in a news release on June 4, 2018, for gross proceeds of \$4,500,000. closed oversubscribed for total gross proceeds of \$4,675,000.*

The non-brokered private placement of 9,350,000 Units at CDN \$0.50 per Unit. The Unit consists of one common share of the Company and one-half of one common share purchase warrant of the Company. Each warrant entitles the holder to purchase one Common Share of the Company at an exercise price of \$0.70.

2. Provide a general overview and discussion of the activities of management.

None to report this period.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to Report.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services have been discontinued.

FORM 7 – MONTHLY PROGRESS REPORT

July 5, 2018

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

The Company entered into a Letter of Intent dated June 21, 2018 (the "LOI") with Full Spectrum Medicinal Inc. ("FSM") regarding a proposed transaction to acquire all of the issued and outstanding securities of FSM (the "Transaction"). The Company will have until September 30, 2018, to conduct due diligence on FSM, with a view to negotiating the terms of a definitive agreement (the "Definitive Agreement") in order to complete the transaction.

Full Spectrum Medicinal Inc. is a privately-owned company formed under the laws of British Columbia. The intent would be for Marapharm to merge the FSM application with its late stage Health Canada application to become a Licensed Producer. The goal would be to become one of the best organic cannabis Licensed Producers specializing in premium flower on a commercial scale. This would set a new standard for quality, cost of production and profit. To read the LOI in detail please visit www.marapharm.com.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None to report this period.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None to report this period.

8. **Describe the acquisition of new customers or loss of customers.**

None to report this period.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None to report this period.

- 10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.**

There is no new hiring, no terminations and no lay-offs.

- 11. Report on any labour disputes and resolutions of those disputes if applicable.**

There are no labour disputes.

- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

Marapharm was served with a notice of claim by Armadillo Resources Inc. for unpaid rent. On May 1, 2018, the judge dismissed the claim and the matter has now been concluded.

Marapharm was served with a counterclaim on its existing defamatory lawsuit against Kurt Soost, Evelyn Soost, Kirsti Mattson and Les Kjosness.

- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

The Company continues to pay its bond holders interest from the date of the close as announced by news release on May 8, 2017.

- 14. Provide details of any securities issued and options or warrants granted.**

(1) State aggregate proceeds and intended allocation of proceeds.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	350,000	Stock Options were exercised	The proceeds will be used for the development of the Nevada, Washington, and California projects and for general corporate purposes.
Common Shares	650,000	Stock Options were exercised	Services for Marketing and Consulting.
Common Shares	9,350,000	Private Placement @ \$.50 per share	The proceeds will be used for the development of the Nevada, Washington, and California projects and for general corporate purposes.

FORM 7 – MONTHLY PROGRESS REPORT

July 5, 2018

15. Provide details of any loans to or by Related Persons.

None to report this period.

**16. Provide details of any changes in directors, officers or committee members.
Bradley J. Dixon has agreed to join the Board of Directors of the Company.**

Mr. Dixon is an attorney based in Boise, Idaho and a partner with Givens Pursley LLP. Brad is the co-chair of the Givens Pursley Litigation Group and focuses his practice on a variety of complex commercial litigation matters. In his 18 years of experience, Brad has amassed a significant portfolio of trial experiences in a variety of commercial disputes including secured transactions, real estate, foreclosure, employment, insurance coverage, products liability, federal court practice, and bankruptcy trial practice. Brad is a graduate of Boise State University where he earned a Bachelor of Science in Political Science with an emphasis on constitutional law and public policy. Brad received his Juris Doctor (JD) from Willamette University College of Law in Salem, Oregon.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

With regard to Nevada, the legalization and implementation of the recreational marijuana program.

With regard to Washington, Washington State has dismantled the medical marijuana initiative (I-692) in favour of the more regulated I-502. This removes the medical marijuana cultivators but allows medical dispensaries to dispense medical and recreational marijuana. Have broken in records in subsequent months. As a result of these regulatory changes, marijuana sales in Washington have broken all prior records over the last 4 months.

The Prime Minister of Canada has announced the legalization of recreational marijuana for 2018.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were, is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: July 6, 2018

Linda Sampson
Name of Director or Senior
Officer

"Linda Sampson"
Signature
CEO
Official Capacity

Issuer Details Name of Issuer Marapharm Ventures Inc.	For Month End June 2018	Date of Report YY/MM/D 2018/07/06
Issuer Address 102-1561 Sutherland Avenue		
City/Province/Postal Code Kelowna, BC V1Y 5Y7	Issuer Fax No. ()N/A	Issuer Telephone No. (778)583-4476
Contact Name Linda Sampson	Contact Position CEO	Contact Telephone No. (778) 583-4476
Contact Email Address Office@marapharm.com	Web Site Address www.marapharm.com	

FORM 7 – MONTHLY PROGRESS REPORT

July 5, 2018